חוב לטווח קצר של החברה: Greenwich LifeSciences (GLSI)

Greenwich LifeSciences (GLSI) is developing oncology immunotherapy, yet a lack of stable revenue and negative cash flow leave the business dependent on external investment. The asset's market value dynamics reflect the current indicator 0.00. Growth prospects rely on the development of the GP2 vaccine, which is preparing for a broad market launch following successful FLAMINGO-01 tests and confirmed efficacy in combating relapses.

Short-term debt reflects the total volume of obligations due within one year. Monitoring current debt allows for an assessment of liquidity risk in the event of a sharp decline in cash flows. This metric aggregates all urgent loans and borrowings, determining the company's dependence on external refinancing. For Greenwich LifeSciences (GLSI), this indicator is critical when financing the development of a vaccine against cancer recurrence. Debt control ensures the stability of research within the immunotherapy segment.